BIOWISDOM
APPOINTS CHIEF SCIENTIFIC OFFICER TO BOARD
For
immediate release – 12 May 2003
(22nd
April 2003, Cambridge, UK) Leading provider of Drug Discovery Ontologies
BioWisdom Ltd has appointed its Chief Scientific Officer, Dr Julie Barnes
to its Board of Directors.
The
appointment follows a successful completion of a round of equity
financing, and reflects the need to align the company’s strategic
activities with the needs of its pharmaceutical company customers. Barnes
will use her 15 years experience of the pharmaceutical industry, as well
as her recent experience in knowledge management, to assist in the
strategic growth of the company.
"BioWisdom
has established a lead position in the provision of very high quality and
expertly annotated ontologies for the pharmaceutical industry, focussed on
drug discovery. The key to BioWisdom’s success is to ensure that these
ontologies are applied in ways that transform the way drug discovery
scientists work," said Barnes. "I am very excited about having
the opportunity to contribute to the growing business of BioWisdom at the
board level."
"I
am delighted to have the opportunity to work with Julie at both the
executive and board level. Her experience of the industry has already
proven a critical asset in growing our reputation with our
customers," said Dr Gordon Smith Baxter, CEO of BioWisdom.
“Julie’s strategic contribution to the board will be an additional
benefit to the company"
About
BioWisdom
BioWisdom
Ltd., headquartered in Cambridge UK, established in September 2000, is a
biomedical informatics company developing systems which help R&D
professionals to access critical information and to assist them in the
discovery and development of novel drug therapies. BioWisdom produces
powerful life science ontologies, which describe important discovery
concepts such as targets (e.g. genes and proteins) tissues and disease and
the inter-relationships between them. BioWisdom's Discovery Ontologies
deliver improved searching, integration and navigation through complex
research information.
-ENDS-
For
further information, please contact:
Gordon
Smith Baxter, CEO
BioWisdom
Ltd
Tel:
+44 (0)1223 492100
email:
gordon.baxter@biowisdom.com
http://www.biowisdom.com
